- Home
- JANX vs JJSF Comparison
JANX vs JJSF Comparison
Compare JANX & JJSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- JJSF
- Stock Information
- Founded
- JANX 2017
- JJSF 1971
- Country
- JANX United States
- JJSF United States
- Employees
- JANX N/A
- JJSF N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- JJSF Specialty Foods
- Sector
- JANX Health Care
- JJSF Consumer Staples
- Exchange
- JANX Nasdaq
- JJSF Nasdaq
- Market Cap
- JANX 1.6B
- JJSF N/A
- IPO Year
- JANX 2021
- JJSF N/A
- Fundamental
- Price
- JANX $26.37
- JJSF $115.74
- Analyst Decision
- JANX Strong Buy
- JJSF Buy
- Analyst Count
- JANX 7
- JJSF 2
- Target Price
- JANX $94.29
- JJSF $142.50
- AVG Volume (30 Days)
- JANX 974.6K
- JJSF 144.2K
- Earning Date
- JANX 05-20-2025
- JJSF 05-06-2025
- Dividend Yield
- JANX N/A
- JJSF 2.69%
- EPS Growth
- JANX N/A
- JJSF N/A
- EPS
- JANX N/A
- JJSF 3.89
- Revenue
- JANX $10,588,000.00
- JJSF $1,585,410,000.00
- Revenue This Year
- JANX N/A
- JJSF $5.67
- Revenue Next Year
- JANX $250.58
- JJSF $3.43
- P/E Ratio
- JANX N/A
- JJSF $29.85
- Revenue Growth
- JANX 30.99
- JJSF 0.49
- 52 Week Low
- JANX $22.52
- JJSF $112.27
- 52 Week High
- JANX $71.71
- JJSF $180.80
- Technical
- Relative Strength Index (RSI)
- JANX 39.10
- JJSF 33.60
- Support Level
- JANX $31.34
- JJSF $112.40
- Resistance Level
- JANX $33.97
- JJSF $132.14
- Average True Range (ATR)
- JANX 1.94
- JJSF 4.94
- MACD
- JANX -0.52
- JJSF -1.92
- Stochastic Oscillator
- JANX 22.76
- JJSF 11.03
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.